Hematologic Oncology | Specialty

The hematologic oncology condition center is a comprehensive resource for clinical news and expert insights on hematologic oncology. Read more at OncLive.

FELIX Analysis Highlights Factors Associated With Sustained Remission With Obe-Cel in R/R Acute Lymphoblastic Leukemia

July 14th 2025

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Molecular Insights Guide First-Line and Post-Transplant Strategies in AML

July 14th 2025

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

July 14th 2025

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL

July 11th 2025

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL

July 11th 2025

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML

July 9th 2025

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

Bexobrutideg Earns EMA Orphan Drug Designation for Waldenström Macroglobulinemia

July 9th 2025

Bexobrutideg received European Medicines Agency orphan drug designation for Waldenström macroglobulinemia.

QOL Data With Obe-Cel in Acute Lymphoblastic Leukemia

July 9th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.

Other Key Data in ALL Presented at EHA 2025

July 9th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

Implications of the FDA Approval of Iptacopan for PNH

July 9th 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the implications of the FDA approval of Iptacopan for PNH.

Bezuclastinib Improves TSS in Non-Advanced Systemic Mastocytosis

July 8th 2025

Bezuclastinib improved total symptom score vs placebo in non-advanced systemic mastocytosis, meeting the primary end point of the SUMMIT trial.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Role of C5 Inhibitors in the Management of Paroxysmal Nocturnal Hemoglobinuria

July 2nd 2025

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

Correlation Between Inotuzumab Exposure and Obe-Cel Efficacy in ALL

July 2nd 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Long-Term Data and Predictors of Sustained Remission With Obe-Cel in ALL

July 2nd 2025

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Dr Raza on Early Safety and Efficacy Data With NXC-201 in AL Amyloidosis

July 1st 2025

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.